期刊
KIDNEY INTERNATIONAL REPORTS
卷 7, 期 9, 页码 1939-1950出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.ekir.2022.06.005
关键词
cancer; chemotherapy; chronic kidney disease; clinical trials; onconephrology
Chemotherapeutic agents used to treat cancer often have narrow therapeutic indices and potentially serious toxicities. Limited data on the safe and effective dosing of these drugs in patients with chronic kidney disease (CKD) contribute to the exclusion of CKD patients from cancer drug trials, preventing optimal clinical care for this population.
Chemotherapeutic agents used to treat cancer generally have narrow therapeutic indices along with potentially serious adverse toxicities. Many cancer drugs are at least partially excreted through the kidney and, thus, the availability of accurate data on safe and effective dosing of these drugs in patients with chronic kidney disease (CKD) is essential to guide treatment decisions. Typically, during drug development, initial clinical studies only include patients with normal or only mildly impaired kidney function. In subsequent preregistration studies, a limited number of patients with more severe kidney dysfunction are included. Data obtained from patients with either severe kidney dysfunction (here defined as an estimated glomerular filtration rate [eGFR] < 30 ml/min or stage 4G CKD) or end-stage kidney disease (ESKD) requiring kidney replacement treatment are particularly limited before drug registration and only a minority of new drug applications to the US Food and Drug Administration (FDA) include data from this population. Unfortunately, limited data and/or other safety concerns may result in a manufacturer statement that the drug is contraindicated in patients with advanced kidney disease, which hinders access to potentially beneficial drugs for these patients. This systemic exclusion of patients with CKD from cancer drug trials remains an unsolved problem, which prevents provision of optimal clinical care for these patients, raises questions of inclusion, diversity, and equity. In addition, with the aging of the population, there are increasing numbers of patients with CKD and cancer who face these issues. In this review, we evaluate the scientific basis to exclude patients with CKD from cancer trials and propose a comprehensive strategy to address this problem. 2022 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据